Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
BK-218 is a novel cephalosporin with a dual route of administration and spectrum of activity most similar to that of second-generation cephalosporins. BK-218 was active against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis but strains resistant to penicillins had higher MICs. BK-218 had greater activity (8-fold) than cefuroxime or cefaclor against oxacillin-susceptible Staphylococcus spp. Moderate BK-218 activity was observed against Neisseria gonorrhoeae and commonly isolated Enterobacteriaceae such as Escherichia coli (MIC90, 1 mg/l), Klebsiella spp. (MIC90, 2 mg/l), and Proteus mirabilis (MIC90, 2 mg/l). The following organisms were generally BK-218-resistant (MIC90, greater than 16 mg/l): Bacteroides fragilis, Pseudomonas spp., Acinetobacter spp., Xanthomonas maltophilia, Citrobacter spp., Enterobacter spp., indole-positive Proteus, Serratia spp., enterococci and oxacillin-resistant staphylococci.
Johnson
D M
DM
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
Jones
R N
RN
D002433:Cefaclor / Q000494:pharmacology; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000201:enzymology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases
D002511:Cephalosporins; C063639:BK 218; D002939:Ciprofloxacin; D002433:Cefaclor; D020682:Cefixime; D001618:beta-Lactamases; D002439:Cefotaxime; D002444:Cefuroxime